Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis

Darae Kim1, Ga Yeon Lee1, Jin-Oh Choi1, Kihyun Kim2, Seok Jin Kim2 & Eun-Seok Jeon1

A 12-lead ECG is a simple and less costly measure to assess cardiac amyloidosis and may reflect the infiltrative nature of cardiac amyloidosis and have prognostic value for predicting overall survival in patients with cardiac AL amyloidosis. Therefore, we investigated the associations of surface ECG parameters with left ventricular (LV) global longitudinal strain (GLS) and prognosis in patients with cardiac AL amyloidosis. We performed a multi-center, retrospective analysis of 102 biopsy-proven cardiac AL amyloidosis patients. Baseline studies included 12-lead surface ECG and echocardiography, with two-dimensional strain analysis performed within one month of diagnosis. From the Kaplan-Meier survival analysis, patients with prolonged QTc (≥483 msec) had significantly poorer survival. ECG scores were assigned according to presence of prolonged QTc (≥483 msec) and abnormal QRS axis, and the study participants were divided into three groups according to ECG score. Mean absolute value of LV GLS and regional LV longitudinal strain (LS) differed significantly among the three groups and decreased in a stepwise manner as ECG score increased. Log NT-proBNP increased in a stepwise manner as ECG score increased. Prolonged QTc (≥483 msec) and abnormal QRS axis showed significant incremental values in addition to the revised Mayo stage. The presence of prolonged QTc (≥483 msec) and abnormal QRS axis showed significant incremental values for overall mortality rates. In addition, ECG scores consisting of presence of prolonged QTc (≥483 msec), and abnormal QRS axis showed good association with longitudinal LV dysfunction and NT-proBNP. ECG finding may provide prognostic additional information regarding prognosis of AL amyloidosis with cardiac involvement.

Primary light-chain (AL) amyloidosis is a plasma cell disorder marked by the deposition of immunoglobulin-derived amyloid in multiple organs, including the heart. Cardiac involvement is characterized by infiltrative cardiomyopathy, and it is the major determinant of overall survival in light-chain (AL) amyloidosis patients. Feasibility of intensive treatment and quality of life are often affected by cardiac involvement1. Therefore, assessing cardiac burden of amyloidosis is important for prognosis and future treatment strategy. Previous studies suggested that left ventricular (LV) global longitudinal strain (GLS), measured from two dimensional echocardiography with strain analysis has prognostic value in patients with AL amyloidosis and correlate with amyloid burdens2–4.

A 12-lead ECG is a simple and less costly measure to assess cardiac amyloidosis. We hypothesized that the features of a surface 12-lead ECG would reflect the infiltrative nature of cardiac amyloidosis and have prognostic value for predicting overall survival in patients with cardiac AL amyloidosis. Therefore, we investigated the features of surface ECG for association with prognosis for overall survival in cardiac AL amyloidosis. Also, we explored association of ECG parameters with LV GLS and regional longitudinal strains (LS).

1Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2Division of Hemato-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Correspondence and requests for materials should be addressed to E.-S.J. (email: eunseok.jeon@samsung.com)
Results

Baseline characteristics. During the median follow-up of 23 months, a total of 43 patients died. The mean age of all study participants was 61.6 years, and 63% were men. At baseline, a total of 48 patients (47%) were classified as revised Mayo Stage IV, and all other patients were at Stage III (Table 1). Low voltage in limb leads was the most prevalent abnormal finding (59%), followed by poor R progression (53%) and pseudoinfarction pattern (47%). The mean absolute value of LV GLS was $-10.2\%\pm 4.2\%$. Regional LV LS showed a relative apical sparing pattern, and basal LV LS showed the lowest absolute value.

| Table 1. Baseline characteristics of all patients. Median (range), mean ± SD, eGFR: estimated glomerular filtration rate. LV, left ventricle; LA, left atrium; GLS, global longitudinal strain; LS, longitudinal strain. |
|---|---|
| **Age (years)** | $61.6\pm 10.8$ |
| **Men, n (%)** | $64 (63)$ |
| **Body surface area (m²)** | $1.66\pm 0.19$ |
| **New York Heart Association class, n (%)** | |
| I | $20 (19)$ |
| II | $64 (63)$ |
| III | $15 (15)$ |
| IV | $3 (3)$ |
| **Systolic blood pressure (mmHg)** | $102.0\pm 15.7$ |
| **Diastolic blood pressure (mmHg)** | $64.7\pm 9.4$ |
| **Log NT-proBNP (pg/mL)** | $3.60\pm 0.49$ |
| **Troponin T (ng/mL)** | $0.08\pm 0.05$ |
| **Creatinine (g/dL)** | $1.26\pm 1.33$ |
| **eGFR (mL/min/1.73 m²)** | $75.7\pm 31.8$ |
| **Revised Mayo stage IV, n (%)** | $48 (47)$ |
| **Autologous stem cell transplantation, n (%)** | $15 (15)$ |
| **Chemotherapy, n (%)** | $83 (81)$ |
| **Electrocardiographic parameters** | |
| PR interval (msec) | $180.0\pm 31.5$ |
| Pseudoinfarction pattern, n (%) | $48 (47)$ |
| Poor R wave progression, n (%) | $54 (53)$ |
| **Low voltage, n (%)** | |
| Limb leads | $60 (59)$ |
| Precordial | $5 (5)$ |
| Sokolow index (mm) | $6.1\pm 4.2$ |
| LV hypertrophy pattern, n (%) | $10 (10)$ |
| Fragmented QRS, n (%) | $14 (14)$ |
| QRS axis (°) | $37.0\pm 98.6$ |
| QRS duration (msec) | $99.4\pm 27.5$ |
| QTc (msec) | $466.7\pm 37.5$ |
| **Echocardiographic parameters** | |
| LV end diastolic dimension, mm | $45.6\pm 5.2$ |
| LV end systolic dimension, mm | $30.6\pm 5.0$ |
| **LV thickness, mm** | |
| Interventricular septum | $13.6\pm 2.6$ |
| Posterior wall | $12.7\pm 2.2$ |
| Relative wall thickness | $0.58\pm 0.14$ |
| LV mass index (g/m²) | $143.4\pm 35.9$ |
| LV ejection fraction (%) | $55.1\pm 9.5$ |
| LA volume index (ml/m²) | $50.2\pm 19.8$ |
| Septal E’ velocity (cm/s) | $0.04\pm 0.01$ |
| E/E’ | $22.7\pm 12.1$ |
| LV GLS, % | $-10.2\pm 4.2$ |
| **Regional LV LS, %** | |
| Basal | $-7.35\pm 3.80$ |
| Mid | $-9.50\pm 4.29$ |
| Apex | $-14.0\pm 6.18$ |
Prognostic values of electrographic parameters. The QTc interval showed satisfactory predictive values for overall survival in cardiac AL amyloidosis (Supplementary Fig. 1, cut-off value: 483 msec, sensitivity 53%, specificity 80%, AUC 0.652 [95% CI: 0.536–0.768], p = 0.012). Among the electrocardiographic parameters, prolonged QTc (≥ 483 msec) (p = 0.002, 95% confidence interval: 1.562–9.221), and abnormal QRS axis (p = 0.049, 95% confidence interval: 1.303–4.724) showed significant association with overall mortality from univariate analysis (Table 2). Patients with prolonged QTc (≥ 483 msec) had significantly poorer overall survival rates compared to those without prolonged QTc (< 483 msec) at baseline ECG (Fig. 1A). Patients with abnormal QRS axis showed a trend of worse overall survival rates; however, the p value was not significant (p = 0.055, Fig. 1B).

Table 2. Univariate and multivariate analyses for overall mortality. LV, left ventricle; GLS, global longitudinal strain.

|                     | Univariate analysis |          |          |          |          |          |
|---------------------|---------------------|----------|----------|----------|----------|----------|
|                     | HR (95% CI)         | P value  | HR (95% CI) | P value  |          |          |
| Age, years          | 0.963–1.039         | 0.989    | 0.963–1.039 | 0.989    |          |          |
| Male gender         | 0.442–2.247         | 0.994    | 0.442–2.247 | 0.994    |          |          |
| eGFR (mL/min/1.73 m²) | 0.986–1.015        | 0.932    | 0.986–1.015 | 0.932    |          |          |
| Revised Mayo stage IV | 1.592–8.322      | 0.002    | 0.589–2.645 | 0.564    |          |          |
| Abnormal QRS axis   | 1.004–5.435         | 0.049    | 1.303–4.724 | 0.131    |          |          |
| Prolonged QTc (≥ 483 msec) | 1.562–9.221  | 0.003    | 1.627–2.666 | 0.006    |          |          |
| Poor R progression  | 0.494–2.419         | 0.826    | 0.494–2.419 | 0.826    |          |          |
| Prolonged PR        | 0.321–1.977         | 0.624    | 0.321–1.977 | 0.624    |          |          |
| Low voltage (limb leads), mm | 0.505–2.503    | 0.774    | 0.505–2.503 | 0.774    |          |          |
| Low voltage (Precordial leads), mm | 0.036–3.114 | 0.337    | 0.036–3.114 | 0.337    |          |          |
| Sokolow index <1.5 mV | 0.287–2.605        | 0.717    | 0.287–2.605 | 0.717    |          |          |
| Pseudo-infarct pattern | 0.456–2.223     | 1.006    | 0.456–2.223 | 1.006    |          |          |
| Fragmented QRS      | 0.331–3.232         | 0.954    | 0.331–3.232 | 0.954    |          |          |
| LV hypertrophy pattern | 0.245–3.523       | 0.915    | 0.245–3.523 | 0.915    |          |          |
| QRS duration        | 0.987–1.015         | 0.909    | 0.987–1.015 | 0.909    |          |          |
| Mean LV wall thickness | 0.974–1.269      | 0.118    | 0.974–1.269 | 0.118    |          |          |
| LV GLS              | 1.067–1.258         | <0.001   | 1.004–1.221 | 0.041    |          |          |

Figure 1. (A) Kaplan-Meier survival curves according to presence of prolonged QTc (≥ 483 msec). Patients with prolonged QTc at baseline ECG had significantly worse overall survival rates. (B) Kaplan-Meier survival curves according to presence of abnormal QRS axis. Patients with abnormal QRS axis at baseline ECG showed a trend of poor overall survival, although the p value was not significant (p = 0.055).
Correlation between ECG scores and LV function, NT-proBNP, and prognosis.

The patient’s ECGs were scored by assigning 1 point for each presence of prolonged QTc (≥483 msec) or abnormal QRS axis (ECG scores). The patients were classified into three groups according to ECG score: patients with neither prolonged QTc (≥483 msec) nor abnormal QRS axis (score 0, n=15), patients with either prolonged QTc (≥483 msec) or abnormal QRS axis (score 1, n=39), and patients with both prolonged QTc (≥483 msec) and abnormal QRS axis (score 2, n=48). The mean values of LV GLS, basal LV LS, and apical LV LS differed significantly among the three groups (Fig. 2A–C), and these values decreased in a stepwise manner as the ECG score increased. The mean values of log NT-proBNP differed significantly among the three groups (p<0.001), and these values increased in a stepwise manner as the ECG score increased (Fig. 2D).

Prolonged QTc (≥483 msec) and abnormal QRS axis showed significant incremental values for overall survival in addition to revised Mayo stage (Supplementary Fig. 2). From multivariate modeling, prolonged QTc (≥483 msec) was the only independent electrocardiographic parameter for overall mortality when adjusted by revised Mayo Stage and LV GLS (Table 2).

Discussion

In the present study, we evaluated the associations of surface ECG parameters between LV GLS and prognosis of AL amyloidosis patients with cardiac involvement. To the best of our knowledge, this is the first study to evaluate the prognostic values of prolonged QTc and abnormal QRS axis in patients with cardiac AL amyloidosis by endomyocardial biopsy. We report the following principle findings in patients with cardiac AL amyloidosis: (1) Prolonged QTc (≥483 msec) and abnormal QRS axis showed significant incremental prognostic values in addition to revised Mayo stage; (2) ECG scores which were assigned by presence of prolonged QTc (≥483 msec) and abnormal QRS axis, showed good associations with the mean absolute values of LV GLS and regional LS; and (3) mean values of Log NT-proBNP differed significantly according to ECG score and showed an increasing trend as ECG score increased.

The ECG is a simple and low cost diagnostic evaluation. The diagnostic value of surface ECG for cardiac amyloidosis is well known. However, only a few studies have investigated the prognostic values of surface ECG parameters in the setting of biopsy-proven cardiac amyloidosis. In this study, we hypothesized that surface ECG may reflect the amyloid burden in cardiac AL amyloidosis and, therefore, may associate with LV GLS and prognosis.
Similar to previous studies, the present investigation showed that low voltage in limb leads (59%), poor R progression (53%), and pseudoinfarction (47%) were the most common findings. However, they were not associated with overall survival or LV GLS. A previous study by Cyrille et al. suggested that low voltage QRS, defined as Sokolow index $\leq 1.5$ mV, was independently associated with adverse outcomes in cardiac amyloidosis. In our study, neither Sokolow index $\leq 1.5$ mV nor low voltage QRS (either at limb leads or precordial leads) was associated with overall survival. This difference may result from different study populations. The study by Cyrille et al. included both AL and transthyretin amyloidosis, which have different prognoses and disease profiles. In addition, they included patients with image-based diagnosis of cardiac involvement if the histological documentation of Congo red staining was positive from other organs, which could have missed early involvement of cardiac amyloidosis. As they mentioned in their study, low voltage pattern could be less prevalent in early stages of cardiac amyloidosis. In our study, we included only patients with cardiac AL amyloidosis confirmed by endocardial biopsy, a confirmatory diagnostic method, and there were some patients with equivocal echocardiographic findings even with positive endocardial biopsy. Previous studies have suggested that the presence of pseudoinfarction and fragmented QRS is associated with prognosis in cardiac AL amyloidosis defined by either endomyocardial biopsy or echocardiographic evidence in systemic amyloidosis. However, neither pseudoinfarction nor fragmented QRS showed prognostic value in our study.

A prolonged QTc suggests repolarization abnormality. We speculate that QTc prolongation represents repolarization heterogeneity in cardiac AL amyloidosis, which may be associated with the infiltrative nature of the disease and may reflect amyloid burden. The QTc interval in our study population showed modest correlation with LV GLS ($r = 0.336, p = 0.001$), suggesting an association between LV longitudinal mechanical dysfunction and electrocardiographic repolarization abnormality (Supplementary Fig. 3A). The prognostic value of the QTc interval has been suggested in healthy populations and those with cardiovascular diseases. From our results, prolonged QTc interval remained independently associated with overall mortality, even after adjusting for revised Mayo stage, LV GLS, and other variables. In addition, the QTc interval showed a modest correlation with log NT-proBNP ($r = 0.406, p < 0.001$) (Supplementary Fig. 3B). An abnormal QRS axis also showed significant incremental values in addition to revised Mayo stage and prolonged QTc interval. An abnormal QRS axis may indicate infiltrative burden precluding a normal electrical conduction vector.

We suggested ECG scores consisting of prolonged QTc interval and abnormal QRS axis. LV longitudinal function showed a decreasing trend as scores increased, while log NT-proBNP showed an increasing trend as scored decreased. Our results suggest that ECG scores may reflect amyloid burden in cardiac amyloidosis. Supplementary Table 1 shows the comparisons of baseline characteristics among patients when classified according to ECG score. Baseline clinical characteristics were similar among three groups. Mean LV wall thickness and LV ejection fraction were similar among three groups, but LV end systolic dimensions increased significantly as ECG scores increased. ECG scores were associated with some of ECG parameters. The presence of low voltage QRS in limb leads and pseudoinfarction pattern differed significantly among the three groups, and their prevalence increased as ECG score increased.

**Limitations**

The present study has several limitations that need to be addressed. First, treatment response is an important predictor of survival in AL amyloidosis, but this was not included because evaluation of response status was not achievable due to limited survival of patients in our cohorts. When subgroup analysis was performed according to chemotherapy regimen (Supplementary Table 1), there was no significant difference of overall survival according to chemotherapy regimen (Supplementary Fig. 4). Secondly, we did not include cardiac AL amyloidosis patients with pacemaker implantation or persistent atrial fibrillation. These patients could not be included because GLS is variable in this population subgroup, and this may have induced a selection bias in the population. Thirdly, we did not include more sophisticated QT-related electrocardiographic measures, such as QT dispersion or T peak–T end. The goal of the current study, however, was to assess the prognostic value of simple, readily available, 12-lead surfaces, such as the QTc interval.

In conclusion, the presence of prolonged QTc ($\geq 483$ msec) and abnormal QRS axis showed significant incremental value for overall mortality rate in AL amyloidosis patients with cardiac involvement. ECG scores consist of presence of prolonged QTc ($\geq 483$ msec), and abnormal QRS axis showed good association with longitudinal LV dysfunction and cardiac biomarker, NT-proBNP. Surface ECG findings may provide prognostic additional information regarding prognosis of AL amyloidosis with cardiac involvement.

**Methods**

**Study population.** We retrospectively reviewed the medical records of patients who were diagnosed with systemic amyloidosis from January 2009 to December 2016, at Seoul National University Hospital and Samsung Medical Center. All patients had biopsy-proven amyloidosis confirmed by Congo red staining and immunohistochemistry of any tissue specimen. Cardiac involvement was confirmed by endomyocardial biopsy, and these patients were included in the study. Any patient with poor echocardiographic images, no follow-up information, persistent atrial fibrillation, paced rhythm, or previous history of myocardial infarction was excluded. In total, 102 patients with cardiac AL amyloidosis were analyzed ($n = 69$ from Samsung Medical Center, $n = 33$ from Seoul National University Hospital).

The baseline clinical information, laboratory results from blood samples, 12-lead electrocardiography (ECG), and two-dimensional transthoracic echocardiography at the time of diagnosis were reviewed. The Modification of Diet in Renal Disease (MDRD) equation was used to calculate estimated glomerular filtration rate (eGFR).

The mortality endpoint was defined as the time to all-cause death from baseline for all deceased patients and time to censor date (November 30th, 2017) for all other patients. Date of baseline was within one month of diagnosis. Occurrence and date of death and ongoing survival status were routinely monitored by regular visits or telephone calls. The median follow-up duration of the censored cases was 23.0 ± 26.5 months.
12-lead ECG. Analysis of the baseline standard 12-lead electrocardiogram was performed by two independent readers who were blinded to echocardiographic data, cardiac biomarkers, and clinical data. Baseline ECG was performed within one month of diagnosis.

The baseline 12-lead ECG was analyzed for the following characteristics: rhythm, prolonged PR (> 200 msec) interval, low voltage (defined by amplitude of QRS in each limb lead ≤0.5 mV<sup>16</sup>-<sup>18</sup> or precordial lead ≤1 mV<sup>5</sup>), and pseudo-infarct pattern (defined by pathologic Q waves or QS waves in at least two consecutive leads in the absence of myocardial infarction and left bundle branch block). QRS voltage amplitude was measured as the sum of the S wave in V1 and the R wave in V5 or V6 and presented as the Sokolow index<sup>6</sup>. LV hypertrophy was defined by the Sokolow-Lyon's criteria<sup>19</sup> (S wave in V1 and the R wave in V5 or V6 ≥3.5 mV) and by the Cornell criteria (R wave in aVL and S wave in V3 ≥2.8 mV in men or ≥2 mV in women or R wave in aVL > 1.2 mV)<sup>20</sup>. Patients with left bundle branch block on electrocardiogram were excluded from the analysis of left ventricular hypertrophy and pseudoinfarct<sup>6</sup>. Poor R progression was determined if the R wave in V3 was ≤3 mm. Fragmented QRS was defined by the presence of various RSR’ patterns with or without a Q wave and included an additional R wave (R), notching of the R wave, notching of the downstroke or upstroke of the S wave, and the presence of >1 R’ in two contiguous leads corresponding to a major coronary artery territory<sup>7</sup>. Normal QRS axis was defined as ≥−30° and <90°. The QRS, QT, QT corrected interval (QTc), and PR interval were measured in all patients.

Echocardiography. All patients underwent standard baseline echocardiography according to the previous guidelines using Vivid 7 or Vivid 9 cardiovascular ultrasound system (GE Medical Systems, Horten, Norway)<sup>21</sup>. Left ventricular (LV) end diastolic dimension, end systolic dimension, interventricular septal thickness, LV posterior wall thickness, and left atrial volume index were measured. Mean LV wall thickness was calculated by averaging the thickness of the interventricular septum and the posterior wall. The ratio of early transmitral flow to early septal mitral annular diastolic velocity (E/e’) was measured as an index of LV filling pressure.

For two-dimensional strain analysis, three consecutive cardiac cycles were recorded and averaged, and the frame rates were set to 60–80 frames/sec. The analysis was performed offline using customized software (EchoPAC PC, version 113; GE Medical Systems). The endocardial border of the LV was manually traced from three apical views (apical 4-, 2-, and 3-chamber views) to obtain LV GLS. In addition, regional LV longitudinal strain (LS) values were calculated by averaging six basal, six mid, and six apical segments to obtain basal, mid, and apical LV LS<sup>22,23</sup>.

Statistical analysis. Continuous data were expressed as mean ± standard deviation, and categorical variables were expressed as absolute number (percent). Receiver operating characteristic (ROC) curves were used to assess the predictive accuracy of QTc on overall mortality. Differences in overall survival according to QTc or QRS axis were assessed using log-rank analysis with right censoring and displayed by Kaplan-Meier survival curves. Patients were scored according to presence of QTc ≥483 msec and abnormal QRS axis. Continuous variables were compared among the three groups using one-way ANOVA. Univariate and multivariate Cox proportional hazard analyses were conducted to evaluate associations between baseline variables (clinical and ECG) and overall survival. The incremental prognostic utility of ECG parameters was assessed by comparing the global chi-square values. All analyses were performed using SPSS version 24 (SPSS Inc., Chicago, Ill., USA). A p value < 0.05 was considered statistically significant.

Ethical considerations. This study was approved by the Ethics committee of Samsung Medical Center. Informed consent was obtained from all subjects, and all methods were carried out in accordance with the relevant guidelines and regulations according to the principles expressed in the Declaration of Helsinki. All study protocols were approved by Institutional Review Board at Samsung Medical Center.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

1. Rapezzi, C. et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. *Circulation* **120**, 1203–1212 (2009).
2. Bellavia, D. et al. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. *Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography* **23**, 643–652 (2010).
3. Buss, S. J. et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. *Journal of the American College of Cardiology* **60**, 1067–1076 (2012).
4. Koyama, J. & Falk, R. H. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. *JACC Cardiovasc Imaging* **3**, 333–342 (2010).
5. Raheman, J. E. et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. *J Am Coll Cardiol* **43**, 410–415 (2004).
6. Hamer, J. P., Janssen, S., van Kuijswijk, M. H. & Lie, K. I. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. *Eur J Heart J* **13**, 623–627 (1992).
7. Eirin, A. et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. *Nephrol Dial Transplant* **27**, 1097–1101 (2012).
8. Cyrille, N. B., Goldsmith, J., Alvarez, J. & Maurer, M. S. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. *Am J Cardiol* **114**, 1089–1093 (2014).
9. Perlini, S. et al. Prognostic value of fragmented QRS in cardiac AL amyloidosis. *Int J Cardiol* **167**, 2156–2161 (2013).
10. Zhao, L., Li, J., Tian, Z. & Fang, Q. Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis. *Journal of cardiology* **68**, 426–430 (2016).
11. Hromadka, M. et al. Prolonged Corrected QT Interval as a Predictor of Clinical Outcome in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis 25, 2911–2917 (2016).
12. Buppajarntham, S., Seetha Rammohan, H. R., Junpaparp, P. & Figueredo, V. M. Prognostic value of prolonged QTc interval in patients with acute pulmonary embolism. Acta Cardiol 69, 550–555 (2014).
13. de Bruyne, M. C. et al. QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 97, 467–472 (1998).
14. Porthan, K. et al. Predictive value of electrocardiographic QT interval and T-wave morphology parameters for all-cause and cardiovascular mortality in a general population sample. Heart rhythm 6(1202–1208), 1208 e1201 (2009).
15. Shenthar, J., Deora, S., Rai, M. & Nanjappa Manjunath, C. Prolonged Tpeak-end and Tpeak-end/QT ratio as predictors of malignant ventricular arrhythmias in the acute phase of ST-segment elevation myocardial infarction: a prospective case-control study. Heart rhythm 12, 484–489 (2015).
16. Cheng, Z. et al. Utility of combined indexes of electrocardiography and echocardiography in the diagnosis of biopsy proven primary cardiac amyloidosis. Annals of noninvasive electrocardiology: the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 16, 25–29 (2011).
17. Dubrey, S. W. et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J 134, 994–1001 (1997).
18. Murtagh, B. et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. The American journal of cardiology 95, 535–537 (2005).
19. Sokolow, M. & Lyon, T. P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 37, 161–186 (1949).
20. Falk, R. H. Diagnosis and management of the cardiac amyloidoses. Circulation 112, 2047–2060 (2005).
21. Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28, 1–39 e14 (2015).
22. Phelan, D. et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98, 1442–1448 (2012).
23. Kim, D. et al. Impact of Ambulatory Blood Pressure on Early Cardiac and Renal Dysfunction in Hypertensive Patients without Clinically Apparent Target Organ Damage. Yonsei Med J 59, 265–272 (2018).

Acknowledgements

We thank light chain amyloidosis patients for participating and staffs of amyloid research team in Samsung Medical Centers. This research was supported by funds (code: 2016E6300502) from the Korea Centers for Disease Control and Prevention.

Author Contributions

D.K., G.Y.L. and E.S.J. designed the study. J.C., K.K. and S.J.K. participated in data collection. D.K. participated in data analysis and interpretation, and in the writing of the paper. E.S.J. critically revised the article for important intellectual content.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-44245-9.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019